LSD
LSD-25
METH-LAD
Acid
N,N-Diethyllysergamide
Lysergide
d-Lysergic acid diethylamide
d-Lysergamide, N,N-diethyl
N,N-Diethyl-d-lysergamide
9,10-Didehydro-N,N-diethyl-6-methylergoline-8β-carboxamide

IUPAC: (8β)-N,N-Diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O Molecular weight: 323.432 g/mol InChI Key: VAYOSLLFUXYJDT-RDTXWAMCSA-N

InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1

PubChem CID: 5761; ChemSpider: 5558; Drugs Forum: LSD; Erowid: LSD; Wikipedia: Lysergic acid diethylamide

See also PiHKAL:	#5 ALEPH-4 #6 ALEPH-6 #7 ALEPH-7 #9 ASB #21 3C-BZ #25 3C-E #28 2C-G-3	#30 2C-G-5 #31 2C-G-N #41 2C-T-4 #43 2C-T-7 #52 DESOXY #58 DMMDA #62 DOB	#66 DOET #67 DOI #68 DOM #69 Ψ-DOM #79 F-2 #80 F-22 #81 FLEA	#97 4-MA #100 MDA #101 MDAL #108 MDIP #111 MDMEO #118 MDPR #125 META-DOT	#132 MMDA #134 MMDA-3a #156 4-TM #160 TMA-4 #161 TMA-5 #170 5-TOET
See also TiHKAL:	#1 AL-LAD #2 DBT #6 DMT	#9 DPT #12 ETH-LAD #16 4-HO-DET	#17 4-HO-DIPT #18 4-HO-DMT #19 5-HO-DMT	#28 4,5-MDO-DIPT #37 5-MeO-DIPT #48 α-MT	#51 PRO-LAD #53 T #57 DALT

See also Transcripts: 2.214, 2.247, 2.249, 2.256, 2.267, 2.269, 2.288, 2.317, 2.323.2, 3.330, 3.336, 3.344, 3.366, 3.376, 3.387, 3.398, 3.399, 3.405, 4.469, 4.508, 5.600, 5.601, 5.622, 5.623, 5.624, 5.632, 5.657, 5.658, 5.659, 5.660, 5.662

See also Pharmacology notes II:	app. 2, Abuse week p. 214, LSD: A recalibration p. 247, LSD: Window exploitation studies p. 249, LSD: Window exploitation studies p. 256, LSD: Window exploitation studies p. 267, LSD: Window exploitation studies p. 269, LSD: Calibration p. 288, LSD: Primer studies p. 317, LSD: Primer studies

Regina, MJ. Biochemical changes associated with serotonergic hallucinogens. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 1 Jun 2005. 3431 kB.

Fenderson5555. Total synthesis of lysergic acid via Pd-catalysed domino cyclizations. 4 Dec 2011. 6394 kB.

Fenderson5555. A more modern lysergic acid synthesis. 28 Jun 2011. 3348 kB.

Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1 Jan 1970; pp 21–41. 8647 kB.

Anderson, GM; Braun, G; Braun, U; Nichols, DE; Shulgin, AT. Absolute configuration and psychotomimetic activity. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1978; pp 8–15. 457 kB.

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Veress, T. Study of the extraction of LSD from illicit blotters for HPLC determination. J. Forensic Sci., 1 Sep 1993, 38 (5), 1105–1110. 348 kB. doi:10.1520/JFS13514J

McDonald, P; Martin, CF; Woods, DJ; Baker, PB; Gough, TA. An analytical study of illicit lysergide. J. Forensic Sci., 1 Jan 1984, 29 (1), 120–130. 493 kB. doi:10.1520/JFS11642J

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. doi:10.1371/journal.pone.0009019

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

Fenderson5555. Total synthesis of lysergic acid. 25 Jun 2011. 4413 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

Reissig, CJ. The 5-HT1A receptor and hallucinogens. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 7 Sep 2006. 943 kB.

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8442 kB.

Chemel, BR. Exploring the molecular determinants of binding selectivity and efficacy for D1 dopamine receptor agonists. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 May 2010. 1919 kB.

Ang, RLL. Molecular basis of the action of hallucinogens. Ph. D. Thesis, New York University, New York, NY, USA, 2010. 2402 kB.

Schindler, EAD. Behavioral and biochemical distinctions in the pharmacology of two common hallucinogens. Ph. D. Thesis, Drexel University, Philadelphia, PA, USA, 1 Apr 2010. 5870 kB.

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

Shulgin, AT. LSD and pregnancy. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jan 2004.

Shulgin, AT. Morning glory seeds. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 17 Oct 2002.

Braden, MR; Nichols, DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol. Pharmacol., 1 Jan 2007, 72 (5), 1200–1209. 487 kB. doi:10.1124/mol.107.039255

Urban, JD; Clarke, WP; Zastrow, M; Nichols, DE; Kobilka, B; Weinstein, H; Javitch, JA; Roth, BL; Christopoulos, A; Sexton, PM; Miller, KJ; . Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 1 Jan 2007, 320 (1), 1–13. 506 kB. doi:10.1124/jpet.106.104463

Passie, T; Halpern, JH; Stichtenoth, DO; Emrich, HM; Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci. Ther., 1 Jan 2008, 14 (4), 295–314. 690 kB. doi:10.1111/j.1755-5949.2008.00059.x

Nichols, DE. Structural correlation between apomorphine and LSD: Involvement of dopamine as well as serotonin in the actions of hallucinogens. J. Theor. Biol., 1 Jun 1976, 59 (1), 167–177. 614 kB. doi:10.1016/S0022-5193(76)80030-6

Lieberman, JA; Mailman, RB; Duncan, G; Sikich, L; Chakos, M; Nichols, DE; Kraus, JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiat., 1 Dec 1998, 44 (11), 1099–1117. 154 kB. doi:10.1016/S0006-3223(98)00187-5

Schulze-Alexandru, M; Kovar, K; Vedani, A. Quasi-atomistic receptor surrogates for the 5-HT2A receptor: A 3D-QSAR study on hallucinogenic substances. Quant. Struct.-Act. Relat., 1 Dec 1999, 18 (6), 548–560. 312 kB. doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B

Blaazer, AR; Smid, P; Kruse, CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem, 15 Sep 2008, 3 (9), 1299–1309. 461 kB. doi:10.1002/cmdc.200800133

Gorodetzky, CW; Isbell, H. A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25. Psychopharmacology, 1 May 1964, 6 (3), 229–233. 317 kB. doi:10.1007/BF00404013

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Jan 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

Wurst, M; Kysilka, R; Flieger, M. Psychoactive tryptamines from Basidiomycetes. Folia Microbiol., 1 Feb 2002, 47 (1), 3–27. 3077 kB. doi:10.1007/BF02818560

Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Selken, JR; Cumbay, MG; Lisnicchia, JG; Nichols, DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioural effects overlap its other properties in rats. Psychopharmacology, 1 Oct 2002, 164 (1), 93–107. 293 kB. doi:10.1007/s00213-002-1141-z

Gomes, MM; Dörr, FA; Catalani, LH; Campa, A. Oxidation of lysergic acid diethylamide (LSD) by peroxidises: a new metabolic pathway. Forensic Toxicol., 1 Jul 2012, 30 (2), 87–97. 632 kB. doi:10.1007/s11419-011-0131-4

Paulke, A; Kremer, C; Wunder, C; Achenbach, J; Djahanschiri, B; Elias, A; Schwed, JS; Hübner, H; Gmeiner, P; Proschak, E; Toennes, SW; Stark, H. Argyreia nervosa (Burm. f.): Receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches. J. Ethnopharmacol., 9 Jul 2013, 148 (2), 492–497. 555 kB. doi:10.1016/j.jep.2013.04.044

Moreno, JL; Holloway, T; Albizu, L; Sealfon, SC; González-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci. Lett., 15 Apr 2011, 493 (3), 76–79. 196 kB. doi:10.1016/j.neulet.2011.01.046

Halberstadt, AL; Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 1 Sep 2011, 61 (3) 364–381. 817 kB. doi:10.1016/j.neuropharm.2011.01.017

Shulgin, AT. Profiles of psychedelic drugs. 9. LSD. J. Psychedelic Drugs, 1 Jan 1980, 12 (2), 173–174. 1025 kB. doi:10.1080/02791072.1980.10471571

Vollenweider, FX; Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci., 1 Sep 2010, 11 (9), 642–651. 588 kB. doi:10.1038/nrn2884

Green, AR. Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. Br. J. Pharmacol., 1 Aug 2008, 1554 (8), 1583–1599. 418 kB. doi:10.1038/bjp.2008.207

Ginzel, KH; Mayer-Gross, W. Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148). Nature, 28 Jul 1956, 178 (4526), 210. 129 kB. doi:10.1038/178210a0

Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Jan 1985, 28 (9), 1252–1255. 583 kB. doi:10.1021/jm00147a022

Glennon, RA; Raghupathi, R; Bartyzel, P; Teitler, M; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1 Feb 1992, 35 (4), 734–740. 1054 kB. doi:10.1021/jm00082a014

Oberlender, R; Pfaff, RC; Johnson, MP; Huang, X; Nichols, DE. Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane. J. Med. Chem., 1 Jan 1992, 35 (2), 203–211. 1143 kB. doi:10.1021/jm00080a001

Schindler, EAD; Dave, KD; Smolock, EM; Aloyo, VJ; Harvey, JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol. Biochem. Behav., 1 Mar 2012, 101 (1), 69–76. 722 kB. doi:10.1016/j.pbb.2011.12.002

Martin, DA; Marona-Lewicka, D; Nichols, DE; Nichols, CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology, 1 Aug 2014, 83, 1–8. 1213 kB. doi:10.1016/j.neuropharm.2014.03.013

Marona-Lewicka, D; Nichols, CD; Nichols, DE. An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology, 1 Sep 2011, 61 (3), 503–512. 803 kB. doi:10.1016/j.neuropharm.2011.02.006

McKenna, DJ; Saavedra, JM. Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain. Eur. J. Pharmacol., 13 Oct 1987, 142 (2), 313–315. 263 kB. doi:10.1016/0014-2999(87)90121-X

LA-111
LSA
LAA
Ergine
d-Lysergamide

IUPAC: (8β)-6-Methyl-9,10-didehydroergoline-8-carboxamide

Formula: C16H17N3O Molecular weight: 267.32568 g/mol InChI Key: GENAHGKEFJLNJB-QMTHXVAHSA-N

InChI=1S/C16H17N3O/c1-19-8-10(16(17)20)5-12-11-3-2-4-13-15(11)9(7-18-13)6-14(12)19/h2-5,7,10,14,18H,6,8H2,1H3,(H2,17,20)/t10-,14-/m1/s1

PubChem CID: 3016; ChemSpider: 390611; Drugs Forum: LSA; Erowid: LSA; Wikipedia: Ergine

See also TiHKAL:	#26 LSD

Kremer, C; Paulke, A; Wunder, C; Toennes, SW. Variable adverse effects in subjects are ingestion of equal doses of Argyreia nervosa seeds. Forensic Sci. Int., 10 Jan 2012, 214 (1–3), e6–e8. 220 kB. doi:10.1016/j.forsciint.2011.06.025

Paulke, A; Kremer, C; Wunder, C; Achenbach, J; Djahanschiri, B; Elias, A; Schwed, JS; Hübner, H; Gmeiner, P; Proschak, E; Toennes, SW; Stark, H. Argyreia nervosa (Burm. f.): Receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches. J. Ethnopharmacol., 9 Jul 2013, 148 (2), 492–497. 555 kB. doi:10.1016/j.jep.2013.04.044

N-Methyllysergamide

IUPAC: (8β)-N,6-Dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C17H19N3O Molecular weight: 281.35226 g/mol InChI Key: NINBUXQQTOVMAB-IAQYHMDHSA-N

InChI=1S/C17H19N3O/c1-18-17(21)11-6-13-12-4-3-5-14-16(12)10(8-19-14)7-15(13)20(2)9-11/h3-6,8,11,15,19H,7,9H2,1-2H3,(H,18,21)/t11-,15-/m1/s1

PubChem CID: 56841679; ChemSpider: 21161369

See also TiHKAL:	#26 LSD

LAE-32
N-Ethyllysergamide

IUPAC: (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C18H21N3O Molecular weight: 295.37884 g/mol InChI Key: VEBWTGYUIBTVNR-MLGOLLRUSA-N

InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1

PubChem CID: 12304966; ChemSpider: 19975296; Wikipedia: LAE-32

See also TiHKAL:	#26 LSD

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

N-Propyllysergamide

IUPAC: (8β)-6-Methyl-N-propyl-9,10-didehydroergoline-8-carboxamide

Formula: C19H23N3O Molecular weight: 309.40542 g/mol InChI Key: VHECNRXVHIGFCO-CXAGYDPISA-N

InChI=1S/C19H23N3O/c1-3-7-20-19(23)13-8-15-14-5-4-6-16-18(14)12(10-21-16)9-17(15)22(2)11-13/h4-6,8,10,13,17,21H,3,7,9,11H2,1-2H3,(H,20,23)/t13-,17-/m1/s1

See also TiHKAL:	#26 LSD

Ergonovine
Ergometrine
N-(1-Hydroxypropan-2-yl)lysergamide

IUPAC: (8β)-N-(1-Hydroxypropan-2-yl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C19H23N3O2 Molecular weight: 325.40482 g/mol InChI Key: WVVSZNPYNCNODU-STQVRIHGSA-N

InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11?,13-,17-/m1/s1

PubChem CID: 443884; ChemSpider: 390049; Wikipedia: Ergometrine

See also TiHKAL:	#26 LSD

Paulke, A; Kremer, C; Wunder, C; Achenbach, J; Djahanschiri, B; Elias, A; Schwed, JS; Hübner, H; Gmeiner, P; Proschak, E; Toennes, SW; Stark, H. Argyreia nervosa (Burm. f.): Receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches. J. Ethnopharmacol., 9 Jul 2013, 148 (2), 492–497. 555 kB. doi:10.1016/j.jep.2013.04.044

N-Butyllysergamide

IUPAC: (8β)-N-Butyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O Molecular weight: 323.432 g/mol InChI Key: PZRGRDXQFPWKCS-RDTXWAMCSA-N

InChI=1S/C20H25N3O/c1-3-4-8-21-20(24)14-9-16-15-6-5-7-17-19(15)13(11-22-17)10-18(16)23(2)12-14/h5-7,9,11,14,18,22H,3-4,8,10,12H2,1-2H3,(H,21,24)/t14-,18-/m1/s1

PubChem CID: 3039392; ChemSpider: 2302861

See also TiHKAL:	#26 LSD

LSB
LAMPA
2-Butyllysergamide
Lysergic acid methylpropylamide
N-Butan-2-yllysergamide

IUPAC: (8β)-N-(Butan-2-yl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O Molecular weight: 323.432 g/mol InChI Key: NYFSQPDQLFFBRA-OLTOQGTGSA-N

InChI=1S/C20H25N3O/c1-4-12(2)22-20(24)14-8-16-15-6-5-7-17-19(15)13(10-21-17)9-18(16)23(3)11-14/h5-8,10,12,14,18,21H,4,9,11H2,1-3H3,(H,22,24)/t12?,14-,18-/m1/s1

ChemSpider: 23241709; Wikipedia: Lysergic acid 2-butyl amide

See also TiHKAL:	#26 LSD

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Jan 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

Nichols, DE; Monte, A; Huang, X; Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Sci., 15 Dec 1995, 73 (1–2), 117–119. 267 kB. doi:10.1016/0166-4328(96)00080-0

Oberlender, R; Pfaff, RC; Johnson, MP; Huang, X; Nichols, DE. Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane. J. Med. Chem., 1 Jan 1992, 35 (2), 203–211. 1143 kB. doi:10.1021/jm00080a001

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

Methergine
Methylergonovine
Methylergometrine
N-(1-Hydroxybutan-2-yl)lysergamide

IUPAC: (8β)-N-(1-Hydroxybutan-2-yl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O2 Molecular weight: 339.4314 g/mol InChI Key: UNBRKDKAWYKMIV-VZGYSGOJSA-N

InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14?,18-/m1/s1

PubChem CID: 8226; ChemSpider: 102713; Wikipedia: Methylergometrine

See also TiHKAL:	#26 LSD

N-Pentyllysergamide

IUPAC: (8β)-6-Methyl-N-pentyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: ZWLCMQVCVMIVGG-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-3-4-5-9-22-21(25)15-10-17-16-7-6-8-18-20(16)14(12-23-18)11-19(17)24(2)13-15/h6-8,10,12,15,19,23H,3-5,9,11,13H2,1-2H3,(H,22,25)/t15-,19-/m1/s1

PubChem CID: 15815935

See also TiHKAL:	#26 LSD

N-Pentan-2-yllysergamide

IUPAC: (8β)-6-Methyl-N-(pentan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: JGLCNUHMSLNTLJ-NWLOPNIYSA-N

InChI=1S/C21H27N3O/c1-4-6-13(2)23-21(25)15-9-17-16-7-5-8-18-20(16)14(11-22-18)10-19(17)24(3)12-15/h5,7-9,11,13,15,19,22H,4,6,10,12H2,1-3H3,(H,23,25)/t13?,15-,19-/m1/s1

PubChem CID: 10427207; ChemSpider: 23240517

See also TiHKAL:	#26 LSD

Nichols, DE; Monte, A; Huang, X; Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Sci., 15 Dec 1995, 73 (1–2), 117–119. 267 kB. doi:10.1016/0166-4328(96)00080-0

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1 Jan 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

LSP
N-Pentan-3-yllysergamide

IUPAC: (8β)-6-Methyl-N-(pentan-3-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: ZQONRMXCBQXYCK-AUUYWEPGSA-N

InChI=1S/C21H27N3O/c1-4-15(5-2)23-21(25)14-9-17-16-7-6-8-18-20(16)13(11-22-18)10-19(17)24(3)12-14/h6-9,11,14-15,19,22H,4-5,10,12H2,1-3H3,(H,23,25)/t14-,19-/m1/s1

PubChem CID: 10019984; ChemSpider: 8195557

See also TiHKAL:	#26 LSD

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1 Jan 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

N-Hexyllysergamide

IUPAC: (8β)-N-Hexyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: KJCRMZZACWZRNL-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-3-4-5-6-10-23-22(26)16-11-18-17-8-7-9-19-21(17)15(13-24-19)12-20(18)25(2)14-16/h7-9,11,13,16,20,24H,3-6,10,12,14H2,1-2H3,(H,23,26)/t16-,20-/m1/s1

See also TiHKAL:	#26 LSD

N-Heptyllysergamide

IUPAC: (8β)-N-Heptyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C23H31N3O Molecular weight: 365.51174 g/mol InChI Key: MDMVZMYXEOCIOT-DYESRHJHSA-N

InChI=1S/C23H31N3O/c1-3-4-5-6-7-11-24-23(27)17-12-19-18-9-8-10-20-22(18)16(14-25-20)13-21(19)26(2)15-17/h8-10,12,14,17,21,25H,3-7,11,13,15H2,1-2H3,(H,24,27)/t17-,21-/m1/s1

See also TiHKAL:	#26 LSD

N-Heptan-2-yllysergamide

IUPAC: (8β)-N-(Heptan-2-yl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C23H31N3O Molecular weight: 365.51174 g/mol InChI Key: HTJZHVCGODLWLI-NZAAYYPMSA-N

InChI=1S/C23H31N3O/c1-4-5-6-8-15(2)25-23(27)17-11-19-18-9-7-10-20-22(18)16(13-24-20)12-21(19)26(3)14-17/h7,9-11,13,15,17,21,24H,4-6,8,12,14H2,1-3H3,(H,25,27)/t15?,17-,21-/m1/s1

PubChem CID: 10361495; ChemSpider: 23240347

See also TiHKAL:	#26 LSD

Nichols, DE; Monte, A; Huang, X; Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Sci., 15 Dec 1995, 73 (1–2), 117–119. 267 kB. doi:10.1016/0166-4328(96)00080-0

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1 Jan 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

DAM-57
N,N-Dimethyllysergamide

IUPAC: (8β)-N,N,6-Trimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C18H21N3O Molecular weight: 295.37884 g/mol InChI Key: FWHSERNVTGTIJE-MLGOLLRUSA-N

InChI=1S/C18H21N3O/c1-20(2)18(22)12-7-14-13-5-4-6-15-17(13)11(9-19-15)8-16(14)21(3)10-12/h4-7,9,12,16,19H,8,10H2,1-3H3/t12-,16-/m1/s1

PubChem CID: 199478; ChemSpider: 172668; Wikipedia: DAM-57

See also TiHKAL:	#26 LSD

Bailey, K; Grey, AA. A conformational study of lysergic acid and iso-lysergic acid dialkylamides by proton magnetic resonance spectroscopy. Can. J. Chem., 1 Dec 1972, 50 (23), 3876–3885. 342 kB. doi:10.1139/v72-611

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

N-Ethyl-N-methyllysergamide

IUPAC: (8β)-N-Ethyl-N,6-dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C19H23N3O Molecular weight: 309.40542 g/mol InChI Key: BROWGWCWLHAXPI-CXAGYDPISA-N

InChI=1S/C19H23N3O/c1-4-21(2)19(23)13-8-15-14-6-5-7-16-18(14)12(10-20-16)9-17(15)22(3)11-13/h5-8,10,13,17,20H,4,9,11H2,1-3H3/t13-,17-/m1/s1

See also TiHKAL:	#26 LSD

LMP
N-Methyl-N-propyllysergamide

IUPAC: (8β)-N,6-Dimethyl-N-propyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O Molecular weight: 323.432 g/mol InChI Key: CZRJGQXHVRNZRZ-RDTXWAMCSA-N

InChI=1S/C20H25N3O/c1-4-8-22(2)20(24)14-9-16-15-6-5-7-17-19(15)13(11-21-17)10-18(16)23(3)12-14/h5-7,9,11,14,18,21H,4,8,10,12H2,1-3H3/t14-,18-/m1/s1

PubChem CID: 497668

See also TiHKAL:	#26 LSD

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

MIPLA
LA-Me/iso
Lamide
N-Isopropyl-N-methyllysergamide

IUPAC: (8β)-N,6-Dimethyl-N-(propan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O Molecular weight: 323.432 g/mol InChI Key: ROICYBLUWUMJFF-RDTXWAMCSA-N

InChI=1S/C20H25N3O/c1-12(2)23(4)20(24)14-8-16-15-6-5-7-17-19(15)13(10-21-17)9-18(16)22(3)11-14/h5-8,10,12,14,18,21H,9,11H2,1-4H3/t14-,18-/m1/s1

Wikipedia: Methylisopropyllysergamide

See also TiHKAL:	#26 LSD

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Jan 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8442 kB.

N-Methyl-N-(1-phenylpropan-2-yl)lysergamide

IUPAC: (8β)-N,6-Dimethyl-N-(1-phenylpropan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C26H29N3O Molecular weight: 399.52796 g/mol InChI Key: XLCLTSBDVIHWOC-GXQNRAESSA-N

InChI=1S/C26H29N3O/c1-17(12-18-8-5-4-6-9-18)29(3)26(30)20-13-22-21-10-7-11-23-25(21)19(15-27-23)14-24(22)28(2)16-20/h4-11,13,15,17,20,24,27H,12,14,16H2,1-3H3/t17?,20-,24-/m1/s1

See also TiHKAL:	#26 LSD

N-Ethyl-N-propyllysergamide

IUPAC: (8β)-N-Ethyl-6-methyl-N-propyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: LRVSYILBFXYJOP-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-4-9-24(5-2)21(25)15-10-17-16-7-6-8-18-20(16)14(12-22-18)11-19(17)23(3)13-15/h6-8,10,12,15,19,22H,4-5,9,11,13H2,1-3H3/t15-,19-/m1/s1

See also TiHKAL:	#26 LSD

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

N,N-Dipropyllysergamide

IUPAC: (8β)-6-Methyl-N,N-dipropyl-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: QKKQYCDPPPJVQI-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-4-9-25(10-5-2)22(26)16-11-18-17-7-6-8-19-21(17)15(13-23-19)12-20(18)24(3)14-16/h6-8,11,13,16,20,23H,4-5,9-10,12,14H2,1-3H3/t16-,20-/m1/s1

See also TiHKAL:	#26 LSD

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

DIPLA
N,N-Diisopropyllysergamide

IUPAC: (8β)-6-Methyl-N,N-di(propan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: UGLFFFFNSMDCNO-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-13(2)25(14(3)4)22(26)16-9-18-17-7-6-8-19-21(17)15(11-23-19)10-20(18)24(5)12-16/h6-9,11,13-14,16,20,23H,10,12H2,1-5H3/t16-,20-/m1/s1

See also TiHKAL:	#26 LSD

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

DAL
N,N-Diallyllysergamide

IUPAC: (8β)-6-Methyl-N,N-di(prop-2-en-1-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C22H25N3O Molecular weight: 347.4534 g/mol InChI Key: VAMQYGHNZLRSSA-OXQOHEQNSA-N

InChI=1S/C22H25N3O/c1-4-9-25(10-5-2)22(26)16-11-18-17-7-6-8-19-21(17)15(13-23-19)12-20(18)24(3)14-16/h4-8,11,13,16,20,23H,1-2,9-10,12,14H2,3H3/t16-,20-/m1/s1

PubChem CID: 57481013; ChemSpider: 21106294; Wikipedia: Diallyllysergamide

See also TiHKAL:	#26 LSD

N,N-Dibutyllysergamide

IUPAC: (8β)-N,N-Dibutyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C24H33N3O Molecular weight: 379.53832 g/mol InChI Key: GVTRJLOTMIDJSS-XMSQKQJNSA-N

InChI=1S/C24H33N3O/c1-4-6-11-27(12-7-5-2)24(28)18-13-20-19-9-8-10-21-23(19)17(15-25-21)14-22(20)26(3)16-18/h8-10,13,15,18,22,25H,4-7,11-12,14,16H2,1-3H3/t18-,22-/m1/s1

See also TiHKAL:	#26 LSD

LSH
Lysergic acid N-(α-hydroxyethyl)amide

IUPAC: (8β)-N-(1-Hydroxyethyl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C18H21N3O2 Molecular weight: 311.37824 g/mol InChI Key: WYTJZJPVCDWOOI-WPJLSRQMSA-N

InChI=1S/C18H21N3O2/c1-10(22)20-18(23)12-6-14-13-4-3-5-15-17(13)11(8-19-15)7-16(14)21(2)9-12/h3-6,8,10,12,16,19,22H,7,9H2,1-2H3,(H,20,23)/t10?,12-,16-/m1/s1

PubChem CID: 134553; ChemSpider: 118592; Wikipedia: Lysergic acid hydroxyethylamide

IPLA
N-Isopropyllysergamide

IUPAC: (8β)-6-Methyl-N-(propan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C19H23N3O Molecular weight: 309.40542 g/mol InChI Key: XSQDFRPRMRYUHM-CXAGYDPISA-N

InChI=1S/C19H23N3O/c1-11(2)21-19(23)13-7-15-14-5-4-6-16-18(14)12(9-20-16)8-17(15)22(3)10-13/h4-7,9,11,13,17,20H,8,10H2,1-3H3,(H,21,23)/t13-,17-/m1/s1

PubChem CID: 5282400; ChemSpider: 4445555

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

EIPLA
N-Ethyl-N-isopropyllysergamide

IUPAC: (8β)-N-Ethyl-6-methyl-N-(propan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: JLPRDEGOBAGMHN-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-5-24(13(2)3)21(25)15-9-17-16-7-6-8-18-20(16)14(11-22-18)10-19(17)23(4)12-15/h6-9,11,13,15,19,22H,5,10,12H2,1-4H3/t15-,19-/m1/s1

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

LA-CH2CF3

IUPAC: (8β)-N-Ethyl-6-methyl-N-(2,2,2-trifluoroethyl)-9,10-didehydroergoline-8-carboxamide

Formula: C20H22F3N3O Molecular weight: 377.4033896 g/mol InChI Key: VAHPXTJQSWECIC-CXAGYDPISA-N

InChI=1S/C20H22F3N3O/c1-3-26(11-20(21,22)23)19(27)13-7-15-14-5-4-6-16-18(14)12(9-24-16)8-17(15)25(2)10-13/h4-7,9,13,17,24H,3,8,10-11H2,1-2H3/t13-,17-/m1/s1

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

N-(3-Phenylbutan-2-yl)lysergamide

IUPAC: (8β)-6-Methyl-N-(3-phenylbutan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C26H29N3O Molecular weight: 399.52796 g/mol InChI Key: HBRPGJLOSRLGCI-WBIUCTKCSA-N

InChI=1S/C26H29N3O/c1-16(18-8-5-4-6-9-18)17(2)28-26(30)20-12-22-21-10-7-11-23-25(21)19(14-27-23)13-24(22)29(3)15-20/h4-12,14,16-17,20,24,27H,13,15H2,1-3H3,(H,28,30)/t16?,17?,20-,24-/m1/s1

Nichols, DE; Monte, A; Huang, X; Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Sci., 15 Dec 1995, 73 (1–2), 117–119. 267 kB. doi:10.1016/0166-4328(96)00080-0

LA-MeO

IUPAC: (8β)-N-Ethyl-N-(methoxymethyl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O2 Molecular weight: 339.4314 g/mol InChI Key: QIWCKKPOQVUMQP-RDTXWAMCSA-N

InChI=1S/C20H25N3O2/c1-4-23(12-25-3)20(24)14-8-16-15-6-5-7-17-19(15)13(10-21-17)9-18(16)22(2)11-14/h5-8,10,14,18,21H,4,9,11-12H2,1-3H3/t14-,18-/m1/s1

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

LPD-824
LA-Pyr
N-Pyrrolidyllysergamide

IUPAC: [(8β)-6-Methyl-9,10-didehydroergolin-8-yl)](pyrrolidin-1-yl)methanone

Formula: C20H23N3O Molecular weight: 321.41612 g/mol InChI Key: SETDYMMXQQXCRP-RDTXWAMCSA-N

InChI=1S/C20H23N3O/c1-22-12-14(20(24)23-7-2-3-8-23)9-16-15-5-4-6-17-19(15)13(11-21-17)10-18(16)22/h4-6,9,11,14,18,21H,2-3,7-8,10,12H2,1H3/t14-,18-/m1/s1

PubChem CID: 200628; ChemSpider: 173678; Wikipedia: LPD-824

See also TiHKAL:	#26 LSD

Oberlender, R; Pfaff, RC; Johnson, MP; Huang, X; Nichols, DE. Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane. J. Med. Chem., 1 Jan 1992, 35 (2), 203–211. 1143 kB. doi:10.1021/jm00080a001

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

N-(2,5-Dihydro-1H-pyrrolyl)lysergamide

IUPAC: 2,5-Dihydro-1H-pyrrol-1-yl[(8β)-6-methyl-9,10-didehydroergolin-8-yl]methanone

Formula: C20H21N3O Molecular weight: 319.40024 g/mol InChI Key: HCABJTFBYLKAMQ-RDTXWAMCSA-N

InChI=1S/C20H21N3O/c1-22-12-14(20(24)23-7-2-3-8-23)9-16-15-5-4-6-17-19(15)13(11-21-17)10-18(16)22/h2-6,9,11,14,18,21H,7-8,10,12H2,1H3/t14-,18-/m1/s1

See also TiHKAL:	#26 LSD

LSD-Pip
LA-Pip
N-Piperidinyllysergamide

IUPAC: [(8β)-6-Methyl-9,10-didehydroergolin-8-yl](piperidin-1-yl)methanone

Formula: C21H25N3O Molecular weight: 335.4427 g/mol InChI Key: URDULHYODQAQTM-DNVCBOLYSA-N

InChI=1S/C21H25N3O/c1-23-13-15(21(25)24-8-3-2-4-9-24)10-17-16-6-5-7-18-20(16)14(12-22-18)11-19(17)23/h5-7,10,12,15,19,22H,2-4,8-9,11,13H2,1H3/t15-,19-/m1/s1

See also TiHKAL:	#26 LSD

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8442 kB.

LSM-775
LA-Morph
N-Morpholinyllysergamide

IUPAC: [(8β)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone

Formula: C20H23N3O2 Molecular weight: 337.41552 g/mol InChI Key: OTQWCDNEJVKXKG-RDTXWAMCSA-N

InChI=1S/C20H23N3O2/c1-22-12-14(20(24)23-5-7-25-8-6-23)9-16-15-3-2-4-17-19(15)13(11-21-17)10-18(16)22/h2-4,9,11,14,18,21H,5-8,10,12H2,1H3/t14-,18-/m1/s1

PubChem CID: 199507; ChemSpider: 172695; Wikipedia: LSM-775

See also TiHKAL:	#26 LSD

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

LA-SS-Az
LSZ
Lysergic acid 2,4-dimethylazetidide

IUPAC: [(2R,4R)-2,4-Dimethylazetidin-1-yl][(8β)-6-methyl-9,10-didehydroergolin-8-yl]methanone

Formula: C21H25N3O Molecular weight: 335.4427 g/mol InChI Key: DUKNIHFTDAXJON-CTQRGLTFSA-N

InChI=1S/C21H25N3O/c1-12-7-13(2)24(12)21(25)15-8-17-16-5-4-6-18-20(16)14(10-22-18)9-19(17)23(3)11-15/h4-6,8,10,12-13,15,19,22H,7,9,11H2,1-3H3/t12-,13-,15+,19+/m0/s1

PubChem CID: 10472143; Wikipedia: Lysergic acid 2,4-dimethylazetidide

Nichols, DE; Frescas, SP; Marona-Lewicka, D; Kurrasch-Orbaugh, DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J. Med. Chem., 1 Jan 2002, 45 (19), 4344–4349. 268 kB. doi:10.1021/jm020153s

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. doi:10.1371/journal.pone.0009019

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8442 kB.

LA-Cispyr
(8β)-8-{[(2R,5S)-2,5-Dimethylpyrrolidin-1-yl]carbonyl}-6-methyl-9,10-didehydroergoline

IUPAC: [(2R,5S)-2,5-Dimethylpyrrolidin-1-yl][(8β)-6-methyl-9,10-didehydroergolin-8-yl]methanone

Formula: C22H27N3O Molecular weight: 349.46928 g/mol InChI Key: BOEUPXAGFWCCGL-FKEXNYPISA-N

InChI=1S/C22H27N3O/c1-13-7-8-14(2)25(13)22(26)16-9-18-17-5-4-6-19-21(17)15(11-23-19)10-20(18)24(3)12-16/h4-6,9,11,13-14,16,20,23H,7-8,10,12H2,1-3H3/t13-,14+,16-,20-/m1/s1

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

LA-RR-Az
Lysergic acid 2,4-dimethylazetidide
(8β)-8-{[(2R,4R)-2,4-Dimethylazetidin-1-yl]carbonyl}-6-methyl-9,10-didehydroergoline

IUPAC: [(2R,4R)-2,4-Dimethylazetidin-1-yl][(8β-6-methyl-9,10-didehydroergolin-8-yl]methanone

Formula: C21H25N3O Molecular weight: 335.4427 g/mol InChI Key: DUKNIHFTDAXJON-DZDCQFRTSA-N

InChI=1S/C21H25N3O/c1-12-7-13(2)24(12)21(25)15-8-17-16-5-4-6-18-20(16)14(10-22-18)9-19(17)23(3)11-15/h4-6,8,10,12-13,15,19,22H,7,9,11H2,1-3H3/t12-,13-,15-,19-/m1/s1

Wikipedia: Lysergic acid 2,4-dimethylazetidide

Nichols, DE; Frescas, SP; Marona-Lewicka, D; Kurrasch-Orbaugh, DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J. Med. Chem., 1 Jan 2002, 45 (19), 4344–4349. 268 kB. doi:10.1021/jm020153s

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. doi:10.1371/journal.pone.0009019

LA-RS-Az
Lysergic acid 2,4-dimethylazetidide
(2R,4S) N-(2,4-Dimethylazetidin-1-yl)lysergamide

IUPAC: [(2R,4S)-2,4-Dimethylazetidin-1-yl][(8β)-6-methyl-9,10-didehydroergolin-8-yl]methanone

Formula: C21H25N3O Molecular weight: 335.4427 g/mol InChI Key: DUKNIHFTDAXJON-FCIKYMEBSA-N

InChI=1S/C21H25N3O/c1-12-7-13(2)24(12)21(25)15-8-17-16-5-4-6-18-20(16)14(10-22-18)9-19(17)23(3)11-15/h4-6,8,10,12-13,15,19,22H,7,9,11H2,1-3H3/t12-,13+,15-,19-/m1/s1

Wikipedia: Lysergic acid 2,4-dimethylazetidide

Nichols, DE; Frescas, SP; Marona-Lewicka, D; Kurrasch-Orbaugh, DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J. Med. Chem., 1 Jan 2002, 45 (19), 4344–4349. 268 kB. doi:10.1021/jm020153s

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. doi:10.1371/journal.pone.0009019

N-(2,3-Dimethylaziridin-1-yl)lysergamide

IUPAC: (2,3-Dimethylaziridin-1-yl)[(8β)-6-methyl-9,10-didehydroergolin-8-yl]methanone

Formula: C20H23N3O Molecular weight: 321.41612 g/mol InChI Key: JWVUYYPVOKOFGC-BVAZEHJSSA-N

InChI=1S/C20H23N3O/c1-11-12(2)23(11)20(24)14-7-16-15-5-4-6-17-19(15)13(9-21-17)8-18(16)22(3)10-14/h4-7,9,11-12,14,18,21H,8,10H2,1-3H3/t11?,12?,14-,18-,23?/m1/s1

ChemSpider: 24604704

12-MeO-6-Me-Ergoline

IUPAC: 12-Methoxy-6-methylergoline

Formula: C16H20N2O Molecular weight: 256.3428 g/mol InChI Key: OYPZSOWGCXXXTG-WCQYABFASA-N

InChI=1S/C16H20N2O/c1-18-7-3-4-11-13(18)8-10-9-17-12-5-6-14(19-2)16(11)15(10)12/h5-6,9,11,13,17H,3-4,7-8H2,1-2H3/t11-,13+/m0/s1

Lee, S. The total syntheses of ring-A substituted ergolines. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 1998. 4709 kB. Note: The structure for Ergoline seems to be 6-Methylergoline.

IUPAC: (6aR,12bR)-7-Methyl-4,6,6a,7,8,12b-hexahydroindolo[4,3-ab]phenanthridin-2-ol

Formula: C19H18N2O Molecular weight: 290.35902 g/mol InChI Key: IGWGEZHNSGQPLV-IEBWSBKVSA-N

InChI=1S/C19H18N2O/c1-21-10-11-4-2-3-5-14(11)19-15-7-13(22)8-16-18(15)12(9-20-16)6-17(19)21/h2-5,7-9,17,19-20,22H,6,10H2,1H3/t17-,19-/m1/s1

Lee, S. The total syntheses of ring-A substituted ergolines. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 1998. 4709 kB. Note: The structure for Ergoline seems to be 6-Methylergoline.

IUPAC: 6-Methyl-9,10-didehydroergolin-13-ol

Formula: C15H16N2O Molecular weight: 240.30034 g/mol InChI Key: OPOQIXLNKCRDLT-CQSZACIVSA-N

InChI=1S/C15H16N2O/c1-17-4-2-3-11-12-6-10(18)7-13-15(12)9(8-16-13)5-14(11)17/h3,6-8,14,16,18H,2,4-5H2,1H3/t14-/m1/s1

Lee, S. The total syntheses of ring-A substituted ergolines. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 1998. 4709 kB. Note: The structure for Ergoline seems to be 6-Methylergoline.

6-Me-Ergoline

IUPAC: 6-Methylergoline

Formula: C15H18N2 Molecular weight: 226.31682 g/mol InChI Key: NNDATQSUZGLGQT-SBXXRYSUSA-N

InChI=1S/C15H18N2/c1-17-7-3-5-11-12-4-2-6-13-15(12)10(9-16-13)8-14(11)17/h2,4,6,9,11,14,16H,3,5,7-8H2,1H3/t11?,14-/m1/s1

ChemSpider: 23190046

Descarboxylysergic acid
Descarboxylysergic acid

IUPAC: 6-Methyl-9,10-didehydroergoline

Formula: C15H16N2 Molecular weight: 224.30094 g/mol InChI Key: AHFZNJIKXMBLTJ-CQSZACIVSA-N

InChI=1S/C15H16N2/c1-17-7-3-5-11-12-4-2-6-13-15(12)10(9-16-13)8-14(11)17/h2,4-6,9,14,16H,3,7-8H2,1H3/t14-/m1/s1

Bach, NJ; Hall, DA; Kornfeld, EC. Descarboxylysergic acid (9,10-didehydro-6-methylergoline). J. Med. Chem., 1 Mar 1974, 17 (3), 312–314. 430 kB. doi:10.1021/jm00249a011

PRO-LAD
6-Propyl-nor-LSD
N,N-Diethyl-6-propyl-6-norlysergamide
6-Norlysergamide, N,N-diethyl-6-propyl
N,N-Diethylnorlysergamide, 6-propyl
6-Propylnorlysergamide, N,N-diethyl
9,10-Didehydro-6-propyl-N,N-diethylergoline-8β-carboxamide

IUPAC: (8β)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: HZKYLVLOBYNKKM-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-4-10-25-14-16(22(26)24(5-2)6-3)11-18-17-8-7-9-19-21(17)15(13-23-19)12-20(18)25/h7-9,11,13,16,20,23H,4-6,10,12,14H2,1-3H3/t16-,20-/m1/s1

PubChem CID: 44457803; ChemSpider: 21106361; Wikipedia: PRO-LAD

See also TiHKAL:	#12 ETH-LAD	#26 LSD

See also Transcripts: 5.652

Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Jan 1985, 28 (9), 1252–1255. 583 kB. doi:10.1021/jm00147a022

N-Hexyllysergamide

IUPAC: (8β)-N-Hexyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: KJCRMZZACWZRNL-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-3-4-5-6-10-23-22(26)16-11-18-17-8-7-9-19-21(17)15(13-24-19)12-20(18)25(2)14-16/h7-9,11,13,16,20,24H,3-6,10,12,14H2,1-2H3,(H,23,26)/t16-,20-/m1/s1

See also TiHKAL:	#26 LSD

N,N-Dipropyllysergamide

IUPAC: (8β)-6-Methyl-N,N-dipropyl-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: QKKQYCDPPPJVQI-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-4-9-25(10-5-2)22(26)16-11-18-17-7-6-8-19-21(17)15(13-23-19)12-20(18)24(3)14-16/h6-8,11,13,16,20,23H,4-5,9-10,12,14H2,1-3H3/t16-,20-/m1/s1

See also TiHKAL:	#26 LSD

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

DIPLA
N,N-Diisopropyllysergamide

IUPAC: (8β)-6-Methyl-N,N-di(propan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C22H29N3O Molecular weight: 351.48516 g/mol InChI Key: UGLFFFFNSMDCNO-OXQOHEQNSA-N

InChI=1S/C22H29N3O/c1-13(2)25(14(3)4)22(26)16-9-18-17-7-6-8-19-21(17)15(11-23-19)10-20(18)24(5)12-16/h6-9,11,13-14,16,20,23H,10,12H2,1-5H3/t16-,20-/m1/s1

See also TiHKAL:	#26 LSD

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.